Skip to Main Content

Paper Details

Cancer therapy shapes the fitness landscape of clonal hematopoiesis.
Nat Genet
336
2020
ASXL1, CH, CH mutation, CHEK2, Cancer, DNA, DNA damage response clones, PPM1D, TP53, cancer, normal tissues, patients, platinum, tMN, tMNs, therapy-related myeloid neoplasms, topoisomerase II
Author NameAffiliation
Kelly L BoltonMemorial Sloan Kettering Cancer Center
Kelly L BoltonMemorial Sloan Kettering Cancer Center
Daniel W KellyMemorial Sloan Kettering Cancer Center
Gunes GundemCenter for Computational Oncology, Memorial Sloan Kettering Cancer Center
Dominik GlodzikCenter for Computational Oncology, Memorial Sloan Kettering Cancer Center
Paul D P PharoahUniversity of Cambridge, Addenbrooke's Hospital
Paul D P PharoahUniversity of Cambridge
Paul D P PharoahUniversity of Cambridge, Addenbrooke's Hospital
Paul D P PharoahUniversity of Cambridge
Christopher J GibsonDana-Farber Cancer Institute
Benjamin L EbertDana-Farber Cancer Institute
Markus BallMoffitt Cancer Center
Markus BallInstitute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne
José Baselga
Larry NortonMemorial Sloan Kettering Cancer Center
Larry NortonWeill Cornell Medical College
Larry NortonMemorial Sloan Kettering Cancer Center
Larry NortonWeill Cornell Medical College
Howard I ScherMemorial Sloan Kettering Cancer Center
Howard I ScherWeill Cornell Medical College
Marc LadanyiMemorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
Michael F BergerMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
Martin S TallmanMemorial Sloan Kettering Cancer Center
Montserrat Garcia-ClosasNational Cancer Institute, National Institutes of Health
Montserrat Garcia-ClosasNational Cancer Institute, National Institutes of Health
Nilanjan ChatterjeeBloomberg School of Public Health Department of Oncology, Johns Hopkins University
  • 1 - 28

Datasets